Advertisement

Ads Placeholder
Loading...

Grifols, S.A.

GRFS•NASDAQ
Healthcare
Drug Manufacturers - General
$8.24
$-0.01(-0.12%)
U.S. Market opens in 3h 59m

Grifols, S.A. (GRFS) Stock Overview

Explore Grifols, S.A.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap7B
P/E Ratio12.14
EPS (TTM)$0.63
ROE0.08%
Fundamental Analysis

AI Price Forecasts

1 Month$6.94
3 Months$9.88
1 Year Target$10.11

GRFS Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Grifols, S.A. (GRFS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 51.63, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $10.11.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 12.14 and a market capitalization of 7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-0.12%
5-Day Change
9.72%
1-Month Change
-4.63%
3-Month Change
-10.82%
6-Month Change
-17.19%
Year-to-Date (YTD) Change
-10.82%
1-Year Change
15.89%
3-Year Change
14.60%
5-Year Change
-51.81%
All-Time (Max) Change
24.47%

Contact Information

https://www.grifols.com
34 93 571 02 21
Avinguda de la Generalitat, 152, Barcelona, NaN, 08174

Company Facts

238,330 Employees
IPO DateJun 2, 2011
CountryES
Actively Trading

Frequently Asked Questions